Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
...new analysis of data from prior clinical trials of ancrod
and updates on the clinical development of their ...m the venom of the Malayan pit viper.
data presented this week in Glasgow draws positive... conclusions that support a new dosing regimen for ancrod
and revised inclusion/exclusion criteria for the c...
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
...cranial hemorrhage in an earlier European
trial of ancrod
(now Viprinex(TM)) for the treatment of acute isch...patients, while the
European ESTAT trial showed an ancrod
treatment outcome similar to placebo,
but a higher... compared, it was noted that
patients treated with ancrod
in ESTAT who had symptomatic intracranial
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
... be based on the first 500 treated patients in the
current trials who have completed their 90 day assessment. If the treatment
effect observed for the ancrod
patients is not better than that observed
for the placebo patients, then the trials will be halted for futility,
indicating that they are unlikely to ...
Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
...of stroke symptoms, there is a substantial unmet medical need
to increase treatment options that are safe and effective to more stroke
Stroke Program I and II studies are Phase 3 clinical trials
currently underway at sites in the United States, various European
countries, Russia, Aust...
Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
months. This is the fifth DSMB meeting for the ancrod
Stroke Program (ASP).
The two trials are:
-- A...zed, Double-Blind, Placebo-Controlled Study of ancrod
in Subjects Beginning Treatment Within 6 Hours...domized, Double-Blind, Placebo-Controlled Study of ancrod
in Subjects Beginning Treatment within 6 Hours...
Presentations at 2007 European Stroke Congress Highlights New
Direction for Viprinex (ancrod)
...ed from the venom of the Malayan pit
data presented this week in Glasgow draws positive...
conclusions that support a new dosing regimen for ancrod
revised inclusion/exclusion criteria for the c...vide
evidence of definitive safety and efficacy of ancrod
stroke in the six-hour time window."